Fresenius Medical Care

Fresenius Medical Care AG & Co. KGaA provides kidney dialysis services through a network of 3,994 outpatient dialysis centers, serving 345,096 patients. The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives. 
With a global headquarters in Bad Homburg vor der Höhe, Germany and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 45 production sites, the largest of which are in the U.S., Germany, and Japan.
The company is 30% owned by Fresenius and, as of 2020, generates around 50% of the group’s revenue.
The company is on the "Best Employers List" published by Forbes.
History.
In 1996, Fresenius SE & Co. KGaA merged its dialysis business into W.R. Grace's National Medical Care to form Fresenius Medical Care.
In 2000, the company plead guilty to billing Medicare for unnecessary medical tests and to paying kickbacks for lab business and paid a $486 million fine.
In February 2012, the company acquired Liberty Dialysis Holding, which added 201 clinics, for $1.5 billion.
In March 2012, Rice Powell was appointed CEO. 
In 2013, the company acquired Shiel Medical Laboratory, expanding services to New York City metro area. In December 2017, the company sold this business to Quest Diagnostics.
In February 2019, the company acquired NxStage, a U.S.-based maker of in-home dialysis devices, for $2 billion.
In March 2019, the company paid $231 million to the United States Department of Justice and the U.S. Securities and Exchange Commission to settle allegations of civil bribery to obtain business in Angola, Saudi Arabia, Morocco, and Spain.